232 related articles for article (PubMed ID: 8321905)
1. The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction.
Jafri SM; Zarowitz B; Goldstein S; Lesch M
Prog Cardiovasc Dis; 1993; 36(1):75-83. PubMed ID: 8321905
[TBL] [Abstract][Full Text] [Related]
2. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
[TBL] [Abstract][Full Text] [Related]
3. Role of platelet inhibitor therapy in myocardial infarction.
Stein B; Fuster V
Cardiovasc Drugs Ther; 1989 Dec; 3(6):797-813. PubMed ID: 2487543
[TBL] [Abstract][Full Text] [Related]
4. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Arjomand H; Cohen M; Ezekowitz MD
J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).
Cohen M; Adams PC; Hawkins L; Bach M; Fuster V
Am J Cardiol; 1990 Dec; 66(19):1287-92. PubMed ID: 2244556
[TBL] [Abstract][Full Text] [Related]
6. [Low-dose aspirin in the long-term treatment of the patient with ischemic heart disease].
Magnani B; Semprini F
Cardiologia; 1994 Dec; 39(12 Suppl 1):15-21. PubMed ID: 7634259
[TBL] [Abstract][Full Text] [Related]
7. The use of antithrombotic drugs in older people.
Tufano A; Cerbone AM; Di Minno G
Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
[TBL] [Abstract][Full Text] [Related]
8. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
Newby LK
Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
[TBL] [Abstract][Full Text] [Related]
10. Primary and secondary prevention of arterial thromboembolism.
Verstraete M
Br Med Bull; 1994 Oct; 50(4):946-65. PubMed ID: 7804741
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
[TBL] [Abstract][Full Text] [Related]
12. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
13. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Cohen M; Xiong J; Parry G; Adams PC; Chamberlain D; Wieczorek I; Fox KA; McBride R; Chesebro JH; Fuster V
J Am Coll Cardiol; 1993 Nov; 22(5):1338-43. PubMed ID: 7901254
[TBL] [Abstract][Full Text] [Related]
14. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Anand SS; Yusuf S; Pogue J; Weitz JI; Flather M
Circulation; 1998 Sep; 98(11):1064-70. PubMed ID: 9736592
[TBL] [Abstract][Full Text] [Related]
15. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
17. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
18. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Lopes RD; Li L; Granger CB; Wang TY; Foody JM; Funk M; Peterson ED; Alexander KP
Am J Med; 2012 Sep; 125(9):897-905. PubMed ID: 22795814
[TBL] [Abstract][Full Text] [Related]
20. An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention.
Hinstridge V; Speight TM
Drugs; 1991; 42 Suppl 2():8-20. PubMed ID: 1718703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
